[A23-138] Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-138
Commission:
Commission awarded on 15.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of advanced or unresectable hepatocellular carcinoma in adult patients
Result of dossier assessment:
- Patients with Child-Pugh A or no hepatic cirrhosis: added benefit not proven
- Patients with Child-Pugh B: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A23-138_en